诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVO 诺和诺德

交易中 01-27 15:39:42 EST

62.99

-0.99

-1.55%

最高63.49	最低62.49	成交量1,149万
今开62.90	昨收63.98	日振幅1.56%
总市值2,796亿	流通市值2,008亿	总股本44.39亿
成交额7.23亿	换手率0.36%	流通股本31.88亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVO","market":"US","secType":"STK","nameCN":"诺和诺德","latestPrice":62.9892,"timestamp":1769546381292,"preClose":63.98,"halted":0,"volume":11487231,"delay":0,"changeRate":-0.01548608940293842,"floatShares":3187922885,"shares":4439052849,"eps":3.665526,"marketStatus":"交易中","change":-0.9908,"latestTime":"01-27 15:39:42 EST","open":62.9,"high":63.4852,"low":62.49,"amount":722833206.56883,"amplitude":0.015555,"askPrice":62.99,"askSize":355,"bidPrice":62.98,"bidSize":251,"shortable":3,"etf":0,"ttmEps":3.665526,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1769547600000},"marketStatusCode":2,"adr":1,"adrRate":1,"listingDate":363499200000,"exchange":"NYSE","adjPreClose":63.98,"dividendRate":0.026795,"preHourTrading":{"tag":"盘前","latestPrice":62.93,"preClose":63.98,"latestTime":"09:29 EST","volume":333324,"amount":21087469.53432,"timestamp":1769524199999,"change":-1.05,"changeRate":-0.016411,"amplitude":0.01141},"postHourTrading":{"tag":"盘后","latestPrice":64.05,"preClose":63.98,"latestTime":"19:59 EST","volume":1537210,"amount":98098068.2468,"timestamp":1769475591045,"change":0.07,"changeRate":0.001094,"amplitude":0.008753},"volumeRatio":0.467678,"optionData":{"bulkOrders":[{"symbol":"NVO","call":false,"expireDate":1769749200000,"strike":"58.0","timestamp":1769534581718,"price":0.17,"volume":5079,"amount":86343,"type":"+"}]},"impliedVol":0.5472,"impliedVolPercentile":0.6773},"requestUrl":"/m/hq/s/NVO","defaultTab":"news","newsList":[{"id":"2606244270","title":"花旗：首次覆盖诺和诺德予“中性”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2606244270","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606244270?lang=zh_cn&edition=full","pubTime":"2026-01-27 14:13","pubTimestamp":1769494428,"startTime":"0","endTime":"0","summary":"格隆汇1月27日｜花旗首次覆盖诺和诺德，给予“中性”评级，目标价400丹麦克朗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127141423a6b1ad88&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127141423a6b1ad88&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0162691827.USD","BK4007","NVO","BK4504","LU0106831901.USD","LU0170899867.USD","LU1244550221.USD","LU2125154935.USD","LU0648001328.SGD","LU1093756325.SGD","LU1162221912.USD","BK4599","BK4588","LU0128525689.USD","LU1201861249.SGD","IE00BKVL7J92.USD","LU2456880835.USD","LU0098860793.USD","BK4532","IE00BZ1G4Q59.USD","LU0320765646.SGD","IE00BSNM7G36.USD","LU0130102774.USD","BK4566","LU1093756168.USD","LU2360032135.SGD","LU2125154778.USD","LU0130517989.USD","LU0052756011.USD","BK4207","LU1791807156.HKD","LU0477156953.USD","LU1267930227.SGD","LU0154236417.USD","LU1244550494.USD","LU2417539215.USD","LU1366192091.USD","LU2462157665.USD","BK4534","LU0072461881.USD","LU0310800965.SGD","LU0980610538.SGD","BK4559","LU2236285917.USD","LU1244550577.SGD","BK4585","LU1668664300.SGD"],"gpt_icon":0},{"id":"2606279590","title":"口服GLP-1卖爆了","url":"https://stock-news.laohu8.com/highlight/detail?id=2606279590","media":"氨基观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606279590?lang=zh_cn&edition=full","pubTime":"2026-01-27 10:31","pubTimestamp":1769481115,"startTime":"0","endTime":"0","summary":"而这一次，诺和诺德在口服GLP-1领域，再次占得先机。2025年12月23日，诺和诺德宣布，Wegovy口服片获得FDA批准，成为首个且唯一获批用于成人减重治疗的口服GLP-1类药物。透过这些布局不难看出，国产口服GLP-1成了海外药企角逐的新战场。此前诺和诺德预计，到2030年，口服药物将占据GLP-1市场超过三分之一的份额。而按照口服型Wegovy当前的处方量，口服GLP-1市场还远未触顶。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127105025a6b0f8b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127105025a6b0f8b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ1G4Q59.USD","NVO","LLY","BK4599","LU0154236417.USD","LU1093756168.USD","BK4585","BK4144","LU1093756325.SGD","BK4007","BK4588","BK4590","BK4532","IE00BKVL7J92.USD"],"gpt_icon":1},{"id":"2606246367","title":"速递｜首周处方破两万张！诺和诺德口服减肥药打响反击战","url":"https://stock-news.laohu8.com/highlight/detail?id=2606246367","media":"GLP1减重宝典","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606246367?lang=zh_cn&edition=full","pubTime":"2026-01-26 19:46","pubTimestamp":1769428003,"startTime":"0","endTime":"0","summary":"作为对比，注射版Wegovy在上市初期前两周的处方量约为1600张，而礼来旗下的注射型减肥药Zepbound同期约为7300张。这一结果对诺和诺德而言意义重大。在此背景下，口服Wegovy能否迅速起量，被视为诺和诺德重新稳住减重业务基本盘的关键支点。Rybelsus目前用于2型糖尿病治疗，14毫克剂量下的周均处方量约为5万张，而上市仅两周的口服Wegovy，已接近这一水平的一半，显著高于市场此前的保守预期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126220324a6aeb062&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126220324a6aeb062&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756325.SGD","IE00BKVL7J92.USD","BK4599","BK4585","BK4007","BK4588","IE00BZ1G4Q59.USD","NVO","LU0154236417.USD","BK4532","LU1093756168.USD"],"gpt_icon":1},{"id":"2605298238","title":"诺和诺德口服Wegovy上市首个完整周处方超1.8万，显著领先其他GLP-1药物同期表现","url":"https://stock-news.laohu8.com/highlight/detail?id=2605298238","media":"Minhua笔记","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605298238?lang=zh_cn&edition=full","pubTime":"2026-01-24 15:24","pubTimestamp":1769239499,"startTime":"0","endTime":"0","summary":"诺和诺德的口服Wegovy上市头11天的早期处方数据超出市场预期，显著领先礼来替尔泊肽注射剂同期表现。1月23日发布的一份分析报告显示，口服Wegovy在截至1月16日的一周内共开出了18,410张处方——这是该药自1月5日上市以来的第一个完整周。按照目前的每周处方量来看，口服Wegovy的处方量已经接近Rybelsus总处方量5万张的一半。这款口服减重药的上市进展目前远超之前的其他GLP-1类药物。更重要的是，它并未导致注射用Wegovy的处方量下滑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012415293997a3351b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012415293997a3351b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","BK4590","BK4588","BK4599","LU1093756168.USD","NVO","IE00BZ1G4Q59.USD","LU0154236417.USD","BK4144","LU1093756325.SGD","IE00BKVL7J92.USD","BK4007","BK4585"],"gpt_icon":1},{"id":"2605140947","title":"诺和诺德盘中异动 股价大涨3.04%报64.12美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2605140947","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605140947?lang=zh_cn&edition=full","pubTime":"2026-01-23 23:11","pubTimestamp":1769181061,"startTime":"0","endTime":"0","summary":"北京时间2026年01月23日23时11分，诺和诺德股票出现波动，股价快速上涨3.04%。截至发稿，该股报64.12美元/股，成交量602.618万股，换手率0.14%，振幅1.32%。诺和诺德股票所在的制药行业中，整体涨幅为0.05%。诺和诺德公司简介：诺和诺德在全球品牌糖尿病治疗市场中占据大约三分之一的份额，是世界上领先的糖尿病护理产品供应商。诺和诺德还拥有一个生物制药部门，专注于治疗血友病和其他疾病的蛋白质疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260123231101a44ef5a6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260123231101a44ef5a6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","BK4599","LU1093756325.SGD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU0154236417.USD","BK4585","NVO","BK4007","LU1093756168.USD","BK4588"],"gpt_icon":1},{"id":"2605470620","title":"诺和诺德明星减肥药上市首周，处方量达18410份","url":"https://stock-news.laohu8.com/highlight/detail?id=2605470620","media":"财闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605470620?lang=zh_cn&edition=full","pubTime":"2026-01-23 20:49","pubTimestamp":1769172560,"startTime":"0","endTime":"0","summary":"数据显示，Wegovy减肥药在上市后的前四天内，处方量就达到了3071份。诺和诺德的Wegovy减肥药于2021年6月获得美国FDA批准上市，成为全球首个获批用于慢性体重管理的GLP-1受体激动剂类药物。分析师认为，Wegovy的上市表现强劲，有望在减肥药市场占据一席之地。目前全球减肥药市场规模超过200亿美元，市场前景广阔。诺和诺德、礼来等制药巨头纷纷布局，竞争日趋激烈。未来几年，随着更多创新减肥药物的上市，市场格局有望重塑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260123205314a6a53866&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260123205314a6a53866&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","BK4585","IE00BZ1G4Q59.USD","BK4588","NVO","LU1093756325.SGD","IE00BKVL7J92.USD","BK4599","BK4007","LU0154236417.USD","LU1093756168.USD"],"gpt_icon":1},{"id":"2605082284","title":"千亿糖尿病药市场，谁主沉浮？","url":"https://stock-news.laohu8.com/highlight/detail?id=2605082284","media":"医药地理","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605082284?lang=zh_cn&edition=full","pubTime":"2026-01-23 17:56","pubTimestamp":1769162186,"startTime":"0","endTime":"0","summary":"糖尿病药物作为全球慢病管理的核心治疗手段，其市场规模在持续扩容与迭代，传统药物与新疗法在院内外渠道共同勾勒出该领域格局。中国医药工业信息中心PDB数据显示，2025年Q1-Q3，国内全渠道市场糖尿病治疗药物销售额达887亿元。根据PDB数据显示，近三年糖尿病用药市场呈现连续增长，除MAT22Q3因第六批胰岛素专项集采带来过销售额回落，MAT23Q3、MAT24Q3和MAT25Q3分别增长2.41%、7.83%、4.19%，整体市场增长强劲。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260123202432a44e75cf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260123202432a44e75cf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","BK4599","LU1093756325.SGD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4588","BK4585","LU0154236417.USD","NVO","603259","BK4007","LU1093756168.USD","02359","03320"],"gpt_icon":1},{"id":"2605492403","title":"打通肥胖管理“最后一公里”，诺和诺德行动了！","url":"https://stock-news.laohu8.com/highlight/detail?id=2605492403","media":"医药代表","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605492403?lang=zh_cn&edition=full","pubTime":"2026-01-22 21:05","pubTimestamp":1769087107,"startTime":"0","endTime":"0","summary":"此次诺和诺德牵手多方成立“零售科学减重生态联盟”，将重点推进标准化服务体系建设、零售专业人才培养及行业协作，促进贴近居民生活的体重管理零售服务网络打造，提升专业体重管理服务的可及性与规范性，助力构建“医院—社区—家庭”一体化肥胖管理生态系统，打通体重管理“最后一公里”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122220120953dec59&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122220120953dec59&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","IE00BZ1G4Q59.USD","NVO","LU0154236417.USD","IE00BKVL7J92.USD","LU1093756168.USD","BK4585","BK4599","BK4588","LU1093756325.SGD","BK4007"],"gpt_icon":1},{"id":"2605460826","title":"诺和诺德盘前升逾2% 高盛称司美格鲁肽口服制剂有望在短期内提振市场情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=2605460826","media":"金吾资讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605460826?lang=zh_cn&edition=full","pubTime":"2026-01-22 18:54","pubTimestamp":1769079269,"startTime":"0","endTime":"0","summary":"金吾财讯 | 诺和诺德(NVO)盘前股价上扬，暂升2.09%，报60.56美元。高盛指出，公司近期推出的司美格鲁肽口服制剂有望在短期内提振市场情绪。高盛指出，上半年的市场焦点将集中于诺和诺德司美格鲁肽口服制剂，以及礼来制药的竞品口服药奥福格列肽的上市进展。高盛表示，司美格鲁肽口服制剂应当会在短期内为诺和诺德带来积极的盈利增长动能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122185448a449a480&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122185448a449a480&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4516","LU1894683348.USD","BK4599","IE0004091025.USD","LU2237443622.USD","LU1791807156.HKD","BK4007","IE00BKVL7J92.USD","BK4533","LU1093756325.SGD","LU0742534661.SGD","LU1868837136.USD","LU0251142724.SGD","BK4552","LU2237443465.HKD","LU0096364046.USD","LU0106831901.USD","BK4588","LU2471134879.HKD","LU1868837300.USD","LU1868836757.USD","LU2237443978.SGD","LU2237443382.USD","LU2471134952.CNY","LU1093756168.USD","LU2237443895.HKD","LU2471134796.USD","IE00BSNM7G36.USD","LU1894683264.USD","LU1868836591.USD","IE00BFXG1179.USD","IE00BZ1G4Q59.USD","LU2265009873.SGD","LU2750360997.AUD","LU1868836914.USD","LU2237443549.SGD","LU2471134523.USD","BK4504","IE00B19Z3581.USD","BK4550","LU0061475181.USD","BK4585","IE00B19Z3B42.SGD","LU0345770993.USD","LU1668664300.SGD","BK4127","LU0251131958.USD","BK4532","LU2750360641.GBP","LU0154236417.USD","LU2237438978.USD","NVO","IE0004086264.USD","LU0345770308.USD","LU0048573561.USD","IE0002270589.USD","IE0034235188.USD","LU1804176565.USD"],"gpt_icon":0},{"id":"2605485617","title":"诺和诺德盘中异动 股价大跌3.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605485617","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605485617?lang=zh_cn&edition=full","pubTime":"2026-01-21 22:41","pubTimestamp":1769006476,"startTime":"0","endTime":"0","summary":"北京时间2026年01月21日22时41分，诺和诺德股票出现异动，股价急速跳水3.02%。截至发稿，该股报58.85美元/股，成交量331.548万股，换手率0.07%，振幅2.05%。诺和诺德股票所在的制药行业中，整体涨幅为0.82%。诺和诺德公司简介：诺和诺德在全球品牌糖尿病治疗市场中占据大约三分之一的份额，是世界上领先的糖尿病护理产品供应商。诺和诺德还拥有一个生物制药部门，专注于治疗血友病和其他疾病的蛋白质疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260121224116a44616bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260121224116a44616bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4532","IE00BKVL7J92.USD","LU0154236417.USD","IE00BZ1G4Q59.USD","LU1093756325.SGD","LU1093756168.USD","BK4585","BK4599","BK4007","NVO"],"gpt_icon":1},{"id":"2605780151","title":"诺和诺德的“救援”：与Aspect Biosystems深化合作，推进糖尿病细胞疗法研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2605780151","media":"药研界面","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605780151?lang=zh_cn&edition=full","pubTime":"2026-01-21 14:13","pubTimestamp":1768976002,"startTime":"0","endTime":"0","summary":"美东时间1月20日，诺和诺德与Aspect Biosystems宣布双方合作进入新阶段，共同开发用于糖尿病治疗的先进细胞药物。自2023年起，Aspect与诺和诺德便开始合作研发细胞药物，旨在替代、修复或补充生物功能，以实现真正的疾病修饰疗法。诺和诺德将向Aspect追加股权投资，并提供研究资金，以推动这些潜在治愈性疗法的研发进程。同时，诺和诺德将有资格从Aspect未来的产品销售中获得特许权使用费及里程碑付款。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260121141927a69afa60&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260121141927a69afa60&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BKVL7J92.USD","NVO","BK4585","IE00BZ1G4Q59.USD","BK4599","LU1093756325.SGD","BK4588","BK4532","BK4007","LU0154236417.USD","LU1093756168.USD"],"gpt_icon":1},{"id":"2604888116","title":"诺和诺德投资aspect BioSystems的糖尿病业务。","url":"https://stock-news.laohu8.com/highlight/detail?id=2604888116","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604888116?lang=zh_cn&edition=full","pubTime":"2026-01-20 21:33","pubTimestamp":1768916002,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4532","LU1093756325.SGD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU1093756168.USD","LU0154236417.USD","NVO","BK4599","BK4588","BK4007","BK4585"],"gpt_icon":0},{"id":"2604961481","title":"速递｜诺和诺德，将GLP-1新药战线推进至儿童青少年人群","url":"https://stock-news.laohu8.com/highlight/detail?id=2604961481","media":"GLP1减重宝典","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604961481?lang=zh_cn&edition=full","pubTime":"2026-01-20 17:10","pubTimestamp":1768900241,"startTime":"0","endTime":"0","summary":"整理 | GLP1减重宝典内容团队1 月 19 日，国家药品监督管理局药品审评中心信息显示，诺和诺德旗下 CagriSema 注射液新适应症临床获批，用于在低热量饮食和增加体力活动基础上，8 至 18 岁以下儿童及青少年的长期体重管理。这一进展，标志着 GLP-1 类药物竞争正式从成人肥胖，延伸至更具争议、也更具长期价值的青少年人群。CagriSema 作为胰淀素类似物与 GLP-1 的复方方案，本身就被视为诺和诺德下一代减重核心资产。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260120173543a44073f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260120173543a44073f8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","LU1093756325.SGD","BK4007","BK4532","IE00BZ1G4Q59.USD","BK4585","LU0154236417.USD","NVO","LU1093756168.USD","BK4144","BK4590","IE00BKVL7J92.USD","BK4588"],"gpt_icon":1},{"id":"2604135410","title":"中国药企拿下诺和诺德订单？涉1.8亿元GLP-1原料药","url":"https://stock-news.laohu8.com/highlight/detail?id=2604135410","media":"健识局","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604135410?lang=zh_cn&edition=full","pubTime":"2026-01-19 20:28","pubTimestamp":1768825711,"startTime":"0","endTime":"0","summary":"1月16日，翰宇药业发布公告称：公司与一家客户签订了合同，涉及采购金额1.8亿元的GLP-1原料药。翰宇药业作为原料药市场的先行者，无疑是供应链转移的受益者。2023年9月，翰宇药业发布公告称，旗下子公司武汉翰宇与美国某客户签订累计金额3000万美元的GLP-1多肽原料药。翰宇药业借助向“美国客户”销售GLP-1原料药产品的优势，开始在行业里确立供应商的地位。这笔1.8医院的GLP-1原料订单，能否扭转翰宇药业持续亏损的颓势，目前还不好说。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260119205354a43d0d23&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260119205354a43d0d23&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVO","BK4585","BK4588","BK4144","300199","LU1093756168.USD","LU1093756325.SGD","BK4007","BK4590","LU0154236417.USD","BK4532","BK4599","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD"],"gpt_icon":0},{"id":"2604138006","title":"GLP-1内卷升级！信达“玛仕度肽注射液”& 诺和诺德 “CagriSema注射液”新临床获批！","url":"https://stock-news.laohu8.com/highlight/detail?id=2604138006","media":"新药社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604138006?lang=zh_cn&edition=full","pubTime":"2026-01-19 17:54","pubTimestamp":1768816486,"startTime":"0","endTime":"0","summary":"今日，国家药品监督管理局药品审评中心显示，两款重磅的GLP-1类药再获新适应症临床，GLP-1赛道内卷再次升级：信达生物—玛仕度肽注射液：高血压合并超重/肥胖人群的血压控制。诺和诺德—CagriSema注射液：用于低热量饮食和增加体力活动的基础上，8至18岁以下儿童及青少年的长期体重管理。CagriSema注射液：全球首款复方制剂，突破青少年治疗瓶颈CagriSema是全球首款GLP-1受体激动剂与胰淀素类似物复方制剂，由诺和诺德研发，采用每周一次皮下注射给药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260119195926a72c6366&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260119195926a72c6366&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4590","LU0154236417.USD","IE00BZ1G4Q59.USD","BK4007","BK4599","IE00BKVL7J92.USD","LU1093756325.SGD","BK4588","01801","LU1093756168.USD","BK4585","BK4144","NVO","BK4532"],"gpt_icon":1},{"id":"2604518986","title":"礼来在涨、诺和诺德在跌，口服减肥药的牌桌上坐的是什么庄","url":"https://stock-news.laohu8.com/highlight/detail?id=2604518986","media":"新财富","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604518986?lang=zh_cn&edition=full","pubTime":"2026-01-19 16:03","pubTimestamp":1768809811,"startTime":"0","endTime":"0","summary":"01引言：当两大“减肥药龙头”走出不同的股价曲线如果只看产品线，2025年的礼来和诺和诺德，几乎站在同一条起跑线上：同样押注GLP-1赛道，同样拥有现象级爆款，同样处在全球减肥药需求爆发的风口之上。而在这个问题上，诺和诺德与礼来，给出了截然不同的答案。在很长一段时间里，诺和诺德几乎是减肥药赛道的“确定性代名词”。2025年7月底诺和诺德因下调指引，股价单日暴跌超21%，两日市值蒸发超800亿美元，标志着其增长神话破灭。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260119161548a43c07ad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260119161548a43c07ad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0683600562.USD","IE00BJJMRX11.SGD","LU0238689110.USD","LU1069344957.HKD","LU2089984988.USD","LU1093756325.SGD","BK4532","LU0203201768.USD","LU0882574139.USD","SG9999018865.SGD","LU0353189680.USD","LU1280957306.USD","LU0471298777.SGD","LU0882574055.USD","LU2491049909.HKD","IE00B1XK9C88.USD","LU0058720904.USD","LU2461242641.AUD","LU0823434740.USD","LU2264538146.SGD","GB00BDT5M118.USD","LU2750360997.AUD","IE00B4JS1V06.HKD","LU1868836757.USD","LU2237443549.SGD","LU2087625088.SGD","LU2471134952.CNY","LU0320765059.SGD","IE00BFSS8Q28.SGD","BK4516","LU0316494557.USD","SG9999017495.SGD","LU0094547139.USD","LU2211815571.USD","NVO","LU0061475181.USD","IE00BZ1G4Q59.USD","LU0466842654.USD","LU2237443622.USD","SG9999015952.SGD","LU0820561818.USD","LLY","SG9999015986.USD","LU1061106388.HKD","LU2237443978.SGD","LU2265009873.SGD","LU2468319806.SGD","LU2471134796.USD","LU0786609619.USD","LU0109394709.USD","LU0385154629.USD","LU2236285917.USD","LU0354030438.USD","IE00BWXC8680.SGD","IE0005OL40V9.USD","LU2602419157.SGD","BK4585","IE00BJJMRY28.SGD","LU2491050154.USD","LU2361045086.USD","LU0097036916.USD","LU0006306889.USD","LU1323610961.USD","SG9999018857.SGD","BK4007","IE00B4R5TH58.HKD","LU2456880835.USD","LU1551013342.USD","LU2746668974.SGD","LU0114720955.EUR","LU2063271972.USD","LU0109391861.USD","LU1551013425.SGD","LU1623119135.USD","LU2746668461.USD","SG9999014914.USD","LU0354030511.USD","LU1974910355.USD","SGXZ31699556.SGD","LU0096364046.USD","LU2471134879.HKD","LU1868837300.USD","IE00BK4W5L77.USD","LU0256863902.USD","LU1127390331.HKD","LU1366192091.USD","LU1868836914.USD","IE00BKVL7J92.USD","SG9999015945.SGD","LU2106854487.HKD","IE00BFSS7M15.SGD","LU0823434583.USD","LU1548497426.USD","LU2237438978.USD","IE00B7KXQ091.USD","LU0106261372.USD","SGXZ51526630.SGD","LU2750360641.GBP","LU0471298694.HKD","LU2491050071.SGD","LU0323591593.USD","IE0004445015.USD","LU2462157665.USD","LU1720051017.SGD","SG9999015978.USD","LU0943347566.SGD","LU0198837287.USD","LU2237443895.HKD","LU1035775433.USD","SG9999013999.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU2324357040.USD","SGXZ99366536.SGD","BK4588","LU0417517546.SGD","IE0002141913.USD","LU1804176565.USD","SG9999014880.SGD","LU1023059063.AUD","LU1983299246.USD","IE0009355771.USD","LU0154236417.USD","LU1064131342.USD","LU2112291526.USD","LU0079474960.USD","SGXZ81514606.USD","LU0122379950.USD","IE00BKDWB100.SGD","SG9999014898.SGD","LU0432979614.USD","LU0820561909.HKD","LU0203202063.USD","LU0672654240.SGD","LU0353189763.USD","BK4533","LU2237443465.HKD","LU2237443382.USD","LU2108987350.USD","LU0787776722.HKD","LU0289739699.SGD","LU1291159041.SGD","BK4599","LU0234572021.USD","LU2417539215.USD","LU2023250504.SGD","LU0256863811.USD","LU1720051108.HKD","LU0708995401.HKD","LU0640476718.USD","SG9999014906.USD","LU2168564222.USD","LU2168564065.EUR","LU1232071149.USD","LU1988902786.USD","IE0004445239.USD","IE00BK4W5M84.HKD","LU0823416689.USD","LU2552382215.SGD","LU2168563687.JPY","LU1093756168.USD","LU2552382058.USD","LU0689472784.USD","LU2471134523.USD","LU0456855351.SGD","IE00B1BXHZ80.USD","IE00BKPKM429.USD","LU1267930730.SGD","LU1868837136.USD","LU2357305700.SGD","LU0266013472.USD","LU2361044865.SGD","LU2552382132.HKD","LU1917777945.USD","IE00BJLML261.HKD","LU1989771016.USD","LU1868836591.USD","LU1712237335.SGD","IE00BFTCPJ56.SGD","LU1057294990.SGD","LU2168564149.EUR","LU2360106947.USD","SGXZ57979304.SGD","SG9999001176.USD","BK4581","IE00BJT1NW94.SGD","BK4534","LU1814569148.SGD","LU2168564495.EUR","LU2361044949.HKD","IE00B775H168.HKD","LU0320765992.SGD","IE00BN29S564.USD","LU0225283273.USD","SG9999001176.SGD","LU0889565916.HKD"],"gpt_icon":1},{"id":"2604494380","title":"礼来VS诺和诺德，互撕！","url":"https://stock-news.laohu8.com/highlight/detail?id=2604494380","media":"药联视界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604494380?lang=zh_cn&edition=full","pubTime":"2026-01-17 11:01","pubTimestamp":1768618899,"startTime":"0","endTime":"0","summary":"诺和诺德率先出手，将司美格鲁肽两个高剂量规格价格最高降幅近48%，调价后月均治疗费用区间为987元至1284元。此番降价本质是市场份额的激烈博弈：诺和诺德意图“以价换量”触达更广泛患者，礼来则欲借高性价比抢占主动权。价格战已同步影响中国市场，礼来替尔泊肽已纳入新版国家医保目录，诺和诺德也下调了司美格鲁肽价格。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260117110833953d21ed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260117110833953d21ed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BFSS8Q28.SGD","LU0109394709.USD","LU1366192091.USD","LU1989771016.USD","LU0061475181.USD","IE00BJJMRY28.SGD","LU1061106388.HKD","SG9999015952.SGD","LU1069344957.HKD","IE00BK4W5M84.HKD","LU1057294990.SGD","LU2456880835.USD","LU2168564495.EUR","LU2108987350.USD","LU0708995401.HKD","LU2089984988.USD","IE0004445015.USD","LU1093756325.SGD","LU0256863811.USD","LU0006306889.USD","IE00BJT1NW94.SGD","LU2237438978.USD","IE00BN29S564.USD","NVO","LU1917777945.USD","LU0787776722.HKD","LU0672654240.SGD","IE0005OL40V9.USD","LU0823434583.USD","LU1291159041.SGD","SG9999014914.USD","LU0316494557.USD","LU1974910355.USD","LU0320765992.SGD","LU1720051017.SGD","LU1023059063.AUD","IE00BKDWB100.SGD","LU2360106947.USD","LU1280957306.USD","LU1868836591.USD","IE00B7KXQ091.USD","LU0122379950.USD","LU2361044865.SGD","LU1035775433.USD","IE00B2B36J28.USD","LU2106854487.HKD","SG9999001176.USD","LU0225283273.USD","LU2063271972.USD","LU2471134879.HKD","IE00BJJMRX11.SGD","LU0471298694.HKD","LU1093756168.USD","LU0683600562.USD","LU0289739699.SGD","LU2237443895.HKD","SG9999015945.SGD","LU2264538146.SGD","BK4085","BK4532","BK4581","LU2750360997.AUD","BK4516","LU0094547139.USD","BK4599","LU2552382215.SGD","LU0320765059.SGD","LU0943347566.SGD","LU0198837287.USD","LU1988902786.USD","LU1064131342.USD","LU0058720904.USD","LU0689472784.USD","LU0882574055.USD","LU2236285917.USD","LLY","LU0238689110.USD","LU0096364046.USD","LU2237443978.SGD","LU0266013472.USD","IE0004445239.USD","BK4534","IE00B4R5TH58.HKD","LU0823416689.USD","LU1551013342.USD","LU2491050071.SGD","LU2602419157.SGD","SGXZ57979304.SGD","IE00BJJMRZ35.SGD","LU0203202063.USD","LU0154236417.USD","SGXZ51526630.SGD","LU1868836757.USD","LU0640476718.USD","LU2471134952.CNY","LU0385154629.USD","IE00BFSS7M15.SGD","LU2324357040.USD","LU0786609619.USD","IE00B775H168.HKD","LU2746668974.SGD","LU1814569148.SGD","LU1983299246.USD","LU2211815571.USD","LU1720051108.HKD","LU0820561818.USD","LU2357305700.SGD","LU2023250504.SGD","LU2746668461.USD","LU0106261372.USD","SG9999001176.SGD","SG9999014898.SGD","IE00BZ1G4Q59.USD","IE00BKPKM429.USD","LU1267930730.SGD","LU0323591593.USD","LU2168564149.EUR","SGXZ81514606.USD","SG9999014906.USD","LU0889565916.HKD","LU1868837136.USD","LU0417517546.SGD","IE0009355771.USD","SG9999018857.SGD","IE00BFTCPJ56.SGD","SG9999015986.USD","SG9999015978.USD","LU2491049909.HKD","LU2168564065.EUR","LU0109391861.USD","LU1232071149.USD","LU2237443622.USD","LU0353189763.USD","LU0882574139.USD","LU2112291526.USD","LU0456855351.SGD","LU0471298777.SGD","LU1127390331.HKD","LU0256863902.USD","IE00BKVL7J92.USD","LU0432979614.USD","LU1548497426.USD","LU1868837300.USD","BK4588","LU0079474960.USD","IE00B1XK9C88.USD","LU2237443549.SGD","LU0353189680.USD","LU2087625088.SGD","LU2462157665.USD","LU2237443465.HKD","LU1868836914.USD","LU2417539215.USD","IE00BJLML261.HKD","GB00BDT5M118.USD","LU1323610961.USD","LU0823434740.USD","SGXZ31699556.SGD","LU2237443382.USD","LU0466842654.USD","LU2461242641.AUD","SGXZ99366536.SGD","LU0354030438.USD","LU1551013425.SGD","LU2471134523.USD","LU2265009873.SGD","LU0203201768.USD","BK4585","LU2471134796.USD","LU0097036916.USD","LU0354030511.USD","LU1623119135.USD","LU2552382058.USD","LU0114720955.EUR","LU2552382132.HKD","SG9999017495.SGD","IE0002141913.USD","BK4533","LU1804176565.USD","BK4007","SG9999014880.SGD","IE00BWXC8680.SGD","LU2491050154.USD","LU2361045086.USD","LU2361044949.HKD","IE00BK4W5L77.USD","LU2468319806.SGD","SG9999013999.USD","LU2750360641.GBP","LU1712237335.SGD","SG9999018865.SGD","IE00B4JS1V06.HKD","LU0234572021.USD","LU2168563687.JPY","IE00B1BXHZ80.USD","LU0820561909.HKD","LU2168564222.USD"],"gpt_icon":1},{"id":"1133864829","title":"异动解读 | Wegovy高剂量版本获英国批准，诺和诺德盘中大涨6.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=1133864829","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133864829?lang=zh_cn&edition=full","pubTime":"2026-01-17 00:12","pubTimestamp":1768579954,"startTime":"0","endTime":"0","summary":"诺和诺德今日盘中大涨6.56%，成为市场焦点。此次股价异动紧随其重磅减肥药Wegovy 7.2mg高剂量版本获英国药品和保健品监管局批准的消息。消息面上，英国批准的7.2mg剂量是目前标准最高剂量的三倍，临床试验显示其减重效果显著：72周后患者平均减重20.7%，三分之一受试者减重超25%。这一突破被视为诺和诺德在GLP-1领域对抗礼来替尔泊肽的关键反击，有望进一步巩固其在全球减重市场的领导地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d806896b6091b132ff78b81fa73d2804","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NVO"],"gpt_icon":0},{"id":"2604990348","title":"涨超5%，司美格鲁肽片剂上市首日开出3071张处方","url":"https://stock-news.laohu8.com/highlight/detail?id=2604990348","media":"华创新药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604990348?lang=zh_cn&edition=full","pubTime":"2026-01-17 00:06","pubTimestamp":1768579560,"startTime":"0","endTime":"0","summary":"诺和诺德周五发布消息称，该公司本月早些时候推出的口服司美格鲁肽片在商业推广的前4天就获得了3071张美国处方。去年12月美国批准了这种药片，使其成为首个获得许可用于治疗肥胖症的口服GLP-1药物，巴克莱的数据显示了这家丹麦制药商在有前景的口服肥胖药物市场巩固其先发优势的初步迹象。根据路透社看到的内部文件，美国食品和药物管理局正对礼来公司生产的口服减肥药进行优先审查，预计将于4月10日做出决定。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260117000926a723a43b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260117000926a723a43b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","BK4588","LU1093756168.USD","NVO","IE00BZ1G4Q59.USD","LU0154236417.USD","BK4585","LU1093756325.SGD","IE00BKVL7J92.USD","BK4007","BK4599"],"gpt_icon":0},{"id":"2604972979","title":"诺和诺德涨逾4.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604972979","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604972979?lang=zh_cn&edition=full","pubTime":"2026-01-16 23:42","pubTimestamp":1768578163,"startTime":"0","endTime":"0","summary":"诺和诺德涨逾4.5%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601163622250558.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"d806896b6091b132ff78b81fa73d2804","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601163622250558.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1093756168.USD","BK4588","LU1093756325.SGD","BK4007","BK4532","BK4599","BK4585","IE00BKVL7J92.USD","LU0154236417.USD","NVO","IE00BZ1G4Q59.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novonordisk.com","stockEarnings":[{"period":"1week","weight":0.0265},{"period":"1month","weight":0.221},{"period":"3month","weight":0.2292},{"period":"6month","weight":0.2788},{"period":"1year","weight":-0.2727},{"period":"ytd","weight":0.2575}],"compareEarnings":[{"period":"1week","weight":0.0015},{"period":"1month","weight":0.0035},{"period":"3month","weight":0.0083},{"period":"6month","weight":0.0918},{"period":"1year","weight":0.1394},{"period":"ytd","weight":0.0159}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novo Nordisk A/S成立于1989年，由两家丹麦公司Nordisk Gentofte A/S和Novo Industri A/S合并而成。该公司是一家全球医疗保健公司，也是糖尿病和肥胖症护理领域的全球领导者。该公司拥有广泛的糖尿病和肥胖症护理以及罕见疾病产品组合，包括用于治疗糖尿病和肥胖症的胰高血糖素样肽-1(GLP-1)受体激动剂、现代胰岛素和人胰岛素。","yearOnYearQuotes":[{"month":1,"riseRate":0.533333,"avgChangeRate":0.122092},{"month":2,"riseRate":0.613636,"avgChangeRate":0.028062},{"month":3,"riseRate":0.454545,"avgChangeRate":0.006986},{"month":4,"riseRate":0.613636,"avgChangeRate":0.01505},{"month":5,"riseRate":0.555556,"avgChangeRate":0.018382},{"month":6,"riseRate":0.688889,"avgChangeRate":0.026171},{"month":7,"riseRate":0.488889,"avgChangeRate":-0.001692},{"month":8,"riseRate":0.533333,"avgChangeRate":0.006145},{"month":9,"riseRate":0.555556,"avgChangeRate":-0.002979},{"month":10,"riseRate":0.488889,"avgChangeRate":-0.004606},{"month":11,"riseRate":0.6,"avgChangeRate":0.026574},{"month":12,"riseRate":0.733333,"avgChangeRate":0.048757}],"exchange":"NYSE","name":"诺和诺德","nameEN":"Novo-Nordisk A/S"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺和诺德,NVO,诺和诺德股票,诺和诺德股票老虎,诺和诺德股票老虎国际,诺和诺德行情,诺和诺德股票行情,诺和诺德股价,诺和诺德股市,诺和诺德股票价格,诺和诺德股票交易,诺和诺德股票购买,诺和诺德股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}